China (Shenzhen) Intellectual Property Protection Center, according to the authoritative data of China National Intellectual Property Administration, uses the evaluation system of enterprise patent innovation to comprehensively score the innovation strength of major enterprises in Shenzhen. The scoring indicators include the number of patent applications, the number of relatives, the number of valid patents, the coverage of emerging technologies, the number of patent awards, and the number of times cited.
It aims to better demonstrate the surging vitality of Greater Bay Area's scientific and technological innovation, encourage enterprises to strive for the first place on the road of innovation and development, and fully demonstrate the leading force of Shenzhen's innovation.
202 1 Top 100 list of Shenzhen enterprises' innovation strength (part).
As a national high-tech enterprise rooted in Shenzhen, Hanyu Pharmaceutical has been deeply involved in the field of polypeptide drugs for more than 20 years, and always regards innovation as the top priority of enterprise development. The company has established national and local joint engineering laboratories for polypeptide drugs, domestic first-class professional R&D teams composed of postdoctoral doctors and overseas masters, national postdoctoral workstations and other innovative platforms.
The establishment of innovation department has strengthened the technical strength of R&D center; He has undertaken a number of national projects and won national, provincial and municipal science and technology special awards for many years in a row. Up to now, * * * has obtained 255 domestic patents, including 249 invention patents; Authorized 26 foreign patents.
Eight products of the company passed the consistency evaluation; The company actively cooperates with the Institute of Microbiology of Chinese Academy of Sciences, Shenzhen Third Hospital, National Research Center, Shenzhen Advanced Institute of Chinese Academy of Sciences, Shenzhen Bay Laboratory and other scientific research institutions;
Join hands with domestic and foreign pharmaceutical companies such as China Resources Bio, Hui Ling Pharmaceutical, Minimally Invasive Medical, China Resources Shuanghe (600062) to make generic drugs, promote the layout of innovative drugs, and rapidly promote the research and development, clinical research application and industrialization of innovative drugs such as anti-COVID-19 polypeptide nasal spray drugs and household COVID-19 antigen rapid detection kits.